期刊
PARKINSONISM & RELATED DISORDERS
卷 28, 期 -, 页码 94-99出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2016.04.033
关键词
Peripheral neuropathy; Parkinson's disease; Levodopa; Iatrogenic
资金
- Parkinson's Society Canada
- Alberta Innovates Health Solutions
Introduction: Parkinson's disease (PD) is neurodegenerative movement disorder affecting primarily the central nervous system with several recognized non-motor symptoms that can occur at various stages of the disease. Recently it has been shown that patients with PD may be prone to peripheral nervous system pathology in the form of a peripheral neuropathy (PN). It is unclear if PN is an inherent feature of PD or if it is an iatrogenic effect of the mainstay PD treatment Levodopa. Methods: To determine if peripheral neuropathy occurs in early untreated PD we employed a case control study design using gold standard tests for PN, including neurological examination according to the Utah Early Neuropathy Scale (UENS) and nerve conduction studies, as well as new, more sensitive and informative tests for PN including the skin biopsy and corneal confocal microscopy (CCM). Results: We studied 26 patients with PD and 22 controls using the neurological examination and nerve conduction studies (NCS) and found no significant difference between groups except for some reduced vibration sense in the PD group. Epidermal nerve densities in the skin biopsies were similar between our cohorts. However, using CCM - a more sensitive test and a surrogate marker of small fiber damage in PN, we found that patients with PD had significantly reduced corneal nerve fiber densities and lengths as compared to controls. Conclusions: We conclude that our positive CCM results provide evidence of preclinical PN in newly diagnosed PD patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据